Steven Vernali1, Weston T Waxweiler1, Patrick M Dillon2, Peter A Kanetsky3, Irene Orlow4, Li Luo5, Klaus J Busam4, Anne Kricker6, Bruce K Armstrong6, Hoda Anton-Culver7, Stephen B Gruber8, Richard P Gallagher9, Roberto Zanetti10, Stefano Rosso10, Lidia Sacchetto10,11,12, Terence Dwyer13, Anne E Cust6, David W Ollila14,15, Colin B Begg4, Marianne Berwick5, Nancy E Thomas1,14. 1. Department of Dermatology, University of North Carolina, Chapel Hill. 2. Department of Medicine, University of Virginia, Charlottesville. 3. Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida. 4. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York. 5. Department of Internal Medicine, University of New Mexico Cancer Center, University of New Mexico, Albuquerque. 6. Sydney School of Public Health, University of Sydney, Sydney, New South Wales, Australia. 7. Department of Epidemiology, University of California, Irvine. 8. USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles. 9. Cancer Control Research, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. 10. Piedmont Cancer Registry, Centre for Epidemiology and Prevention in Oncology in Piedmont, Turin, Italy. 11. Politecnico di Torino, Turin, Italy. 12. Universitá degli Studi di Torino, Turin, Italy. 13. George Institute for Global Health, Nuffield Department of Obstetrics and Gynecology, University of Oxford, England. 14. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill. 15. Department of Surgery, University of North Carolina, Chapel Hill.
Abstract
Importance: We previously reported that survival is poorer from histopathologically amelanotic than pigmented melanoma because of more advanced stage at diagnosis. Identifying patients at risk of amelanotic melanoma might enable earlier diagnosis and improved survival; however, the phenotypic characteristics and underlying genetics associated with amelanotic melanoma are unknown. Objective: To determine whether phenotypic characteristics, carriage of MC1R variants, and history of amelanotic melanoma are associated with histopathologically amelanotic melanoma. Design, Setting, and Participants: The Genes, Environment, and Melanoma (GEM) study is an international cohort study that enrolled patients with incident primary cutaneous melanomas from population-based and hospital-based cancer registries (1998 to 2003). The GEM participants included here were 2387 patients with data for phenotypes, MC1R genotype, and primary melanomas scored for histopathologic pigmentation. Of these 2387 patients with incident melanomas scored for pigmentation, 527 had prior primary melanomas also scored for pigmentation. Main Outcomes and Measures: Associations of phenotypic characteristics (freckles, nevi, phenotypic index) and MC1R status with incident amelanotic melanomas were evaluated using logistic regression models adjusted for age, sex, study center, and primary status (single or multiple primary melanoma); odds ratios (ORs) and 95% CIs are reported. Association of histopathologic pigmentation between incident and prior melanomas was analyzed using an exact logistic regression model. Results: This study included 2387 patients (1065 women, 1322 men; mean [SD] age at diagnosis, 58.3 [16.1] years) and 2917 primary melanomas. In a multivariable model including phenotypic characteristics, absence of back nevi, presence of many freckles, and a sun-sensitive phenotypic index were independently associated with amelanotic melanoma. Carriage of MC1R variants was associated with amelanotic melanoma but lost statistical significance in a model with phenotype. Further, patients with incident primary amelanotic melanomas were more likely to have had a prior primary amelanotic melanoma (OR, 4.62; 95% CI, 1.25-14.13) than those with incident primary pigmented melanomas. Conclusions and Relevance: Absence of back nevi, presence of many freckles, a sun-sensitive phenotypic index, and prior amelanotic melanoma increase odds for development of amelanotic melanoma. An increased index of suspicion for melanoma in presenting nonpigmented lesions and more careful examination for signs of amelanotic melanoma during periodic skin examination in patients at increased odds of amelanotic melanoma might lead to earlier diagnosis and improved survival.
Importance: We previously reported that survival is poorer from histopathologically amelanotic than pigmented melanoma because of more advanced stage at diagnosis. Identifying patients at risk of amelanotic melanoma might enable earlier diagnosis and improved survival; however, the phenotypic characteristics and underlying genetics associated with amelanotic melanoma are unknown. Objective: To determine whether phenotypic characteristics, carriage of MC1R variants, and history of amelanotic melanoma are associated with histopathologically amelanotic melanoma. Design, Setting, and Participants: The Genes, Environment, and Melanoma (GEM) study is an international cohort study that enrolled patients with incident primary cutaneous melanomas from population-based and hospital-based cancer registries (1998 to 2003). The GEM participants included here were 2387 patients with data for phenotypes, MC1R genotype, and primary melanomas scored for histopathologic pigmentation. Of these 2387 patients with incident melanomas scored for pigmentation, 527 had prior primary melanomas also scored for pigmentation. Main Outcomes and Measures: Associations of phenotypic characteristics (freckles, nevi, phenotypic index) and MC1R status with incident amelanotic melanomas were evaluated using logistic regression models adjusted for age, sex, study center, and primary status (single or multiple primary melanoma); odds ratios (ORs) and 95% CIs are reported. Association of histopathologic pigmentation between incident and prior melanomas was analyzed using an exact logistic regression model. Results: This study included 2387 patients (1065 women, 1322 men; mean [SD] age at diagnosis, 58.3 [16.1] years) and 2917 primary melanomas. In a multivariable model including phenotypic characteristics, absence of back nevi, presence of many freckles, and a sun-sensitive phenotypic index were independently associated with amelanotic melanoma. Carriage of MC1R variants was associated with amelanotic melanoma but lost statistical significance in a model with phenotype. Further, patients with incident primary amelanotic melanomas were more likely to have had a prior primary amelanotic melanoma (OR, 4.62; 95% CI, 1.25-14.13) than those with incident primary pigmented melanomas. Conclusions and Relevance: Absence of back nevi, presence of many freckles, a sun-sensitive phenotypic index, and prior amelanotic melanoma increase odds for development of amelanotic melanoma. An increased index of suspicion for melanoma in presenting nonpigmented lesions and more careful examination for signs of amelanotic melanoma during periodic skin examination in patients at increased odds of amelanotic melanoma might lead to earlier diagnosis and improved survival.
Authors: Pascale Guitera; Giovanni Pellacani; Kerry A Crotty; Richard A Scolyer; Ling-Xi L Li; Sara Bassoli; Marco Vinceti; Harold Rabinovitz; Caterina Longo; Scott W Menzies Journal: J Invest Dermatol Date: 2010-04-15 Impact factor: 8.551
Authors: Colin B Begg; Amanda J Hummer; Urvi Mujumdar; Bruce K Armstrong; Anne Kricker; Loraine D Marrett; Robert C Millikan; Stephen B Gruber; Hoda Anton Culver; Roberto Zanetti; Richard P Gallagher; Terrence Dwyer; Timothy R Rebbeck; Klaus Busam; Lynn From; Marianne Berwick Journal: Int J Epidemiol Date: 2006-03-23 Impact factor: 7.196
Authors: Susannah E McClain; Kira B Mayo; Amber L Shada; Mark E Smolkin; James W Patterson; Craig L Slingluff Journal: Int J Dermatol Date: 2012-04 Impact factor: 2.736
Authors: Peter A Kanetsky; Timothy R Rebbeck; Amanda J Hummer; Saarene Panossian; Bruce K Armstrong; Anne Kricker; Loraine D Marrett; Robert C Millikan; Stephen B Gruber; Hoda Anton Culver; Roberto Zanetti; Richard P Gallagher; Terence Dwyer; Klaus Busam; Lynn From; Urvi Mujumdar; Homer Wilcox; Colin B Begg; Marianne Berwick Journal: Cancer Res Date: 2006-09-15 Impact factor: 12.701
Authors: David L Duffy; Zhen Z Zhao; Richard A Sturm; Nicholas K Hayward; Nicholas G Martin; Grant W Montgomery Journal: J Invest Dermatol Date: 2009-08-27 Impact factor: 8.551
Authors: Richard A Sturm; Carly Fox; Phil McClenahan; Kasturee Jagirdar; Maider Ibarrola-Villava; Parastoo Banan; Nicola C Abbott; Gloria Ribas; Brian Gabrielli; David L Duffy; H Peter Soyer Journal: J Invest Dermatol Date: 2013-06-17 Impact factor: 8.551
Authors: Nancy E Thomas; Anne Kricker; Weston T Waxweiler; Patrick M Dillon; Klaus J Busman; Lynn From; Pamela A Groben; Bruce K Armstrong; Hoda Anton-Culver; Stephen B Gruber; Loraine D Marrett; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Terence Dwyer; Alison Venn; Peter A Kanetsky; Irene Orlow; Susan Paine; David W Ollila; Anne S Reiner; Li Luo; Honglin Hao; Jill S Frank; Colin B Begg; Marianne Berwick Journal: JAMA Dermatol Date: 2014-12 Impact factor: 10.282
Authors: Paola Ghiorzo; Lorenza Pastorino; Maria A Pizzichetta; Riccardo Bono; Paola Queirolo; Renato Talamini; Giorgio Annessi; William Bruno; Sabina Nasti; Sara Gargiulo; Linda Battistuzzi; Maria C Sini; Giuseppe Palmieri; Giovanna Bianchi Scarrà Journal: Melanoma Res Date: 2009-06 Impact factor: 3.599
Authors: Jiali Han; Peter Kraft; Hongmei Nan; Qun Guo; Constance Chen; Abrar Qureshi; Susan E Hankinson; Frank B Hu; David L Duffy; Zhen Zhen Zhao; Nicholas G Martin; Grant W Montgomery; Nicholas K Hayward; Gilles Thomas; Robert N Hoover; Stephen Chanock; David J Hunter Journal: PLoS Genet Date: 2008-05-16 Impact factor: 5.917
Authors: Zachary H Hopkins; Ryan P Carlisle; Zachary E Frost; Julia A Curtis; Laura K Ferris; Aaron M Secrest Journal: J Clin Aesthet Dermatol Date: 2021-12
Authors: Nancy E Thomas; Sharon N Edmiston; Irene Orlow; Peter A Kanetsky; Li Luo; David C Gibbs; Eloise A Parrish; Honglin Hao; Klaus J Busam; Bruce K Armstrong; Anne Kricker; Anne E Cust; Hoda Anton-Culver; Stephen B Gruber; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Lidia Sacchetto; Terence Dwyer; David W Ollila; Colin B Begg; Marianne Berwick; Kathleen Conway Journal: J Invest Dermatol Date: 2018-05-09 Impact factor: 8.551